A 28.3% shareholder bloc locks in support for the Synlogic–Caldera merger, removing a key obstacle to closing.
SYBX has more than doubled off its 52-week low of $0.54 on elevated volume (45× avg).
Summary
A 28.3% shareholder group has agreed to support Synlogic's merger with Caldera Therapeutics, providing a critical vote bloc and reducing deal uncertainty.
Key Events · M&A and Partnerships · SYBX
-
28.3% Holder Enters Support Agreement
Funicular Funds, Cable Car Capital, and Jacob Ma-Weaver, owning 3,312,219 shares (28.3% of Synlogic), signed a support agreement to vote for the Caldera merger and against competing proposals.
-
Irrevocable Proxy Granted
The group granted an irrevocable proxy to Synlogic to vote their shares on the merger, preventing any last-minute change of heart.
-
Transfer Restrictions Imposed
The support agreement restricts the group from selling or transferring their shares, ensuring their stake remains committed through the vote.
-
Merger Agreement Announced Same Day
The support agreement was executed concurrently with the definitive merger agreement between Synlogic and Caldera Therapeutics, disclosed in an 8-K earlier today.
Analysis · SYBX · Life Sciences
A support agreement signed by Funicular Funds, Cable Car Capital, and Jacob Ma-Weaver — together controlling 28.3% of Synlogic — commits their votes to the Caldera Therapeutics merger. By locking in this substantial bloc, the risk of a shareholder rebellion drops sharply and the path to closing becomes far more certain. The pact also restricts share sales and grants an irrevocable proxy, underscoring a major investor's strong commitment.
How filings like this one have moved
In the 30 days to Oct 3, 2026, 36.7% of the 1072 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.61%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SYBX was trading at $1.12 on OTC in the Life Sciences sector, with a market capitalization of approximately $13.1M. The 52-week trading range was $0.54 to $1.96. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.